Advanced Filters
noise
Found 64,783 clinical trials
J José AE Barletta, MD

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy.

18 years of age Male Phase 4

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

18 years of age All Phase 1/2
M Maikel P prof. Peppelenbosch, MD, PhD

Milk Consumption and Blood Microbiome in Healthy Volunteers

The goal of this study is to learn if cfDNA of milk-associated intestinal bacteria (MAIB) is detectable in the bloodstream. The primary question it aims to answer is: Does milk consumption simultaneously increase the number of MAIB cfDNA counts in blood samples, as it does in fecal samples? Researchers will …

18 - 65 years of age All Phase N/A
S Sheng-Li Xue, M.D.

Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia

This prospective, multi-center, randomized, controlled Phase II study is to compare the therapeutic efficacy and side effect of VACl (Venetoclax,Azacitidine,Cladribine) alternating with VACh (Venetoclax,Azacitidine,Chidamide), VACl, VACh and VA in newly diagnosed adult acute myeloid leukemia (AML) patients ineligible for intensive therapy or declining. Cladribine is a purine analogue widely used …

18 years of age All Phase 2
S Stevie Rozing, MD

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

The goal of this clinical trial is to learn if the drug called rituximab causes remission in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The aim is to investigate this in two types of patients, those who are newly diagnosed, and those who are already being treated and are dependent …

18 - 80 years of age All Phase 3
J Jun Young Lee

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

Comparison nafamostat and low molecular weight heparin among dialysis patients

18 - 99 years of age All Phase N/A
E Ellen de Jonge

The Efficacy of Treatments to Improve Self-esteem

The goal of this study is to examine the effectivity of two self-esteem interventions (COMET (Korrelboom) and CBT (De Neef)) in a general psychiatric population. The main questions it aims to answer are: is there a difference between the two interventions in effectiveness on increasing self-esteem? is there a difference …

18 - 65 years of age All Phase N/A
N Nutrition and Dietetics

Acceptability, Gastrointestinal Tolerance, Compliance and Palatability Study.

Acceptability, compliance and palatability study.

1 - 16 years of age All Phase N/A
A Andrew Yates, B.A.

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues. Patients may have improved DME with anti-VEGF therapy and ranibizumab has been found to reduce central macular thickness (CMT) with anti-VEGF therapy following vitrectomy. Those patients still require intravitreal injections but the …

21 years of age All Phase 4
T Tianshu Liu

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

18 - 75 years of age All Phase 2

Simplify language using AI